DK261490D0 - New pharmaceutical compound - Google Patents

New pharmaceutical compound

Info

Publication number
DK261490D0
DK261490D0 DK261490A DK261490A DK261490D0 DK 261490 D0 DK261490 D0 DK 261490D0 DK 261490 A DK261490 A DK 261490A DK 261490 A DK261490 A DK 261490A DK 261490 D0 DK261490 D0 DK 261490D0
Authority
DK
Denmark
Prior art keywords
pharmaceutical compound
new pharmaceutical
epi
patients
useful
Prior art date
Application number
DK261490A
Other languages
Danish (da)
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to DK261490A priority Critical patent/DK261490D0/da
Publication of DK261490D0 publication Critical patent/DK261490D0/da
Priority to HU9301253A priority patent/HUT64236A/hu
Priority to DK91919614.7T priority patent/DK0558529T3/da
Priority to AT91919614T priority patent/ATE132757T1/de
Priority to EP91919614A priority patent/EP0558529B1/en
Priority to CA002095356A priority patent/CA2095356A1/en
Priority to CZ93786A priority patent/CZ282497B6/cs
Priority to PCT/DK1991/000317 priority patent/WO1992007584A1/en
Priority to JP3518142A priority patent/JPH06502171A/ja
Priority to RU93032613A priority patent/RU2127600C1/ru
Priority to AU88711/91A priority patent/AU657926B2/en
Priority to UA93004415A priority patent/UA35567C2/uk
Priority to DE69116380T priority patent/DE69116380T2/de
Priority to SK428-93A priority patent/SK282516B6/sk
Priority to ES91919614T priority patent/ES2083597T3/es
Priority to GR960400902T priority patent/GR3019514T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK261490A 1990-10-31 1990-10-31 New pharmaceutical compound DK261490D0 (da)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DK261490A DK261490D0 (da) 1990-10-31 1990-10-31 New pharmaceutical compound
ES91919614T ES2083597T3 (es) 1990-10-31 1991-10-18 Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
CZ93786A CZ282497B6 (cs) 1990-10-31 1991-10-18 Farmaceutický přípravek k léčbě prodloužené doby koagulace
JP3518142A JPH06502171A (ja) 1990-10-31 1991-10-18 長期凝血時間の処置のための薬品製剤
AT91919614T ATE132757T1 (de) 1990-10-31 1991-10-18 Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
EP91919614A EP0558529B1 (en) 1990-10-31 1991-10-18 Pharmaceutical preparation for the treatment of prolonged coagulation time
CA002095356A CA2095356A1 (en) 1990-10-31 1991-10-18 Pharmaceutical preparation for the treatment of prolonged coagulation time
HU9301253A HUT64236A (en) 1990-10-31 1991-10-18 Process for the production of medical preparatives applicable for the treatment of enlarged time of coagulation
PCT/DK1991/000317 WO1992007584A1 (en) 1990-10-31 1991-10-18 Pharmaceutical preparation for the treatment of prolonged coagulation time
DK91919614.7T DK0558529T3 (da) 1990-10-31 1991-10-18 Farmaceutisk præparat til behandling af forlænget koagulationstid
RU93032613A RU2127600C1 (ru) 1990-10-31 1991-10-18 Фармацевтический препарат, обладающий свойством ускорять процесс коагуляции крови, способ ускорения коагуляции крови in vitro и применение ингибитора epi активности в качестве вещества, обладающего свойством ускорять процесс коагуляции крови
AU88711/91A AU657926B2 (en) 1990-10-31 1991-10-18 Pharmaceutical preparation for the treatment of prolonged coagulation time
UA93004415A UA35567C2 (uk) 1990-10-31 1991-10-18 Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
DE69116380T DE69116380T2 (de) 1990-10-31 1991-10-18 Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
SK428-93A SK282516B6 (sk) 1990-10-31 1991-10-18 Farmaceutický prípravok na liečenie pacientov s predĺženým časom zrážania krvi
GR960400902T GR3019514T3 (en) 1990-10-31 1996-04-02 Pharmaceutical preparation for the treatment of prolonged coagulation time

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK261490A DK261490D0 (da) 1990-10-31 1990-10-31 New pharmaceutical compound

Publications (1)

Publication Number Publication Date
DK261490D0 true DK261490D0 (da) 1990-10-31

Family

ID=8113744

Family Applications (2)

Application Number Title Priority Date Filing Date
DK261490A DK261490D0 (da) 1990-10-31 1990-10-31 New pharmaceutical compound
DK91919614.7T DK0558529T3 (da) 1990-10-31 1991-10-18 Farmaceutisk præparat til behandling af forlænget koagulationstid

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK91919614.7T DK0558529T3 (da) 1990-10-31 1991-10-18 Farmaceutisk præparat til behandling af forlænget koagulationstid

Country Status (15)

Country Link
EP (1) EP0558529B1 (cs)
JP (1) JPH06502171A (cs)
AT (1) ATE132757T1 (cs)
AU (1) AU657926B2 (cs)
CA (1) CA2095356A1 (cs)
CZ (1) CZ282497B6 (cs)
DE (1) DE69116380T2 (cs)
DK (2) DK261490D0 (cs)
ES (1) ES2083597T3 (cs)
GR (1) GR3019514T3 (cs)
HU (1) HUT64236A (cs)
RU (1) RU2127600C1 (cs)
SK (1) SK282516B6 (cs)
UA (1) UA35567C2 (cs)
WO (1) WO1992007584A1 (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
GB2268909B (en) * 1992-07-21 1995-10-25 Profy International Corp Unitary loose sheet binder
RU2195676C2 (ru) * 1999-08-26 2002-12-27 Уральская государственная медицинская академия Способ комплексной оценки прогноза эффективности лечения диффузных заболеваний соединительной ткани низкомолекулярными антикоагулянтами
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
AU2001258230A1 (en) * 2000-05-10 2001-11-20 Novo-Nordisk A/S Pharmaceutical composition comprising a factor viia and a tfpi inhibitor
AU2002365131B2 (en) 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
EP1919499A2 (en) * 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
BRPI0914916A2 (pt) 2008-06-30 2015-10-20 Novo Nordisk As anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2010071894A2 (en) 2008-12-19 2010-06-24 Baxter International Inc. Tfpi inhibitors and methods of use
PL2379600T5 (pl) * 2008-12-22 2021-03-08 Novo Nordisk A/S Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
CA2789061A1 (en) * 2010-02-26 2011-09-01 Henrik Parshad Stable antibody containing compositions
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
JP5730983B2 (ja) 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
WO2011147921A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
CN103080135B (zh) 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
CA2867363C (en) 2012-03-21 2023-02-28 Baxter International Inc. Tfpi inhibitors and methods of use
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359463A (en) * 1980-11-26 1982-11-16 Rock Gail A Stabilization of Factor VIII activity in whole blood or blood plasma
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
HU219883B (hu) * 1988-03-17 2001-08-28 Novo-Nordisk A/S Heparinkötő proteinek, ezeket kódoló DNS és a proteineket tartalmazó gyógyszerkészítmények, valamint eljárás ezek előállítására
DK148890D0 (da) * 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat

Also Published As

Publication number Publication date
JPH06502171A (ja) 1994-03-10
DE69116380T2 (de) 1996-07-11
ES2083597T3 (es) 1996-04-16
EP0558529A1 (en) 1993-09-08
SK282516B6 (sk) 2002-10-08
CZ78693A3 (en) 1993-12-15
AU8871191A (en) 1992-05-26
HU9301253D0 (en) 1993-07-28
WO1992007584A1 (en) 1992-05-14
CA2095356A1 (en) 1992-05-01
UA35567C2 (uk) 2001-04-16
CZ282497B6 (cs) 1997-07-16
ATE132757T1 (de) 1996-01-15
EP0558529B1 (en) 1996-01-10
AU657926B2 (en) 1995-03-30
GR3019514T3 (en) 1996-07-31
RU2127600C1 (ru) 1999-03-20
SK42893A3 (en) 1993-09-08
DE69116380D1 (de) 1996-02-22
DK0558529T3 (da) 1996-06-03
HUT64236A (en) 1993-12-28

Similar Documents

Publication Publication Date Title
DK261490D0 (da) New pharmaceutical compound
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
DE59010810D1 (de) Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
ATE169219T1 (de) Behandlung von katarakt mit 15-keto- prostaglandinderivaten
ES2044840T3 (es) Composiciones estabilizadas del activador del plasminogeno de tejido humano.
ES2059121T3 (es) Uso de agentes sensibilizantes de insulina para tratar la hipertension.
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DE68903092D1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
NO890046L (no) Disubstituerte pyridiner.
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
ATE87476T1 (de) Fluessige orale formulierung.
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
DK0669826T3 (da) (-)-Metrifonatholdigt lægemiddel
DE69807200D1 (de) Inklusionskomplexe in waessriger loesung
DE69113437D1 (de) Therapeutische Mittel für diabetisches Gangrän.
DK102988D0 (da) Middel med antidepressiv virkning

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment